Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

Condition:   Refractory Plasma Cell Myeloma Interventions:   Drug: Dexamethasone;   Biological: Elotuzumab;   Drug: Pomalidomide Sponsors:   Mayo Clinic;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials